Krueger GG - Search Results

1

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. Carlin CS, et al. Among authors: krueger jg, krueger gg. J Am Acad Dermatol. 2004 Jun;50(6):859-66. doi: 10.1016/j.jaad.2003.09.014. J Am Acad Dermatol. 2004. PMID: 15153885

2

Consensus workshop on the toxic effects of long-term PUVA therapy.

Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Piepkorn M, Stern RS, Weinstein GD, Whitmore SE. Morison WL, et al. Among authors: krueger gg. Arch Dermatol. 1998 May;134(5):595-8. doi: 10.1001/archderm.134.5.595. Arch Dermatol. 1998. PMID: 9606329 Review.

3

Alefacept therapy produces remission for patients with chronic plaque psoriasis.

Krueger GG, Ellis CN. Krueger GG, et al. Br J Dermatol. 2003 Apr;148(4):784-8. doi: 10.1046/j.1365-2133.2003.05239.x. Br J Dermatol. 2003. PMID: 12752139 Clinical Trial.

4

The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.

Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, Lew-Kaya DA, Lue JC, Sefton J, Chandraratna RA. Krueger GG, et al. Arch Dermatol. 1998 Jan;134(1):57-60. doi: 10.1001/archderm.134.1.57. Arch Dermatol. 1998. PMID: 9449910 Clinical Trial.

5

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

Ellis CN, Krueger GG; Alefacept Clinical Study Group. Ellis CN, et al. Among authors: krueger gg. N Engl J Med. 2001 Jul 26;345(4):248-55. doi: 10.1056/NEJM200107263450403. N Engl J Med. 2001. PMID: 11474662 Clinical Trial.

6

Efficacy and safety of treatment modalities for psoriasis.

Tristani-Firouzi P, Krueger GG. Tristani-Firouzi P, et al. Among authors: krueger gg. Cutis. 1998 Feb;61(2 Suppl):11-21. Cutis. 1998. PMID: 9787987 Review.

7

Systemic corticosteroid use in psoriasis: a national survey of board-certified dermatologists.

Secrest AM, Elkeeb DM, Petron B, Elsensohn A, Edwards LD, Krueger GG, Duffin KC. Secrest AM, et al. Among authors: krueger gg. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e116-e117. doi: 10.1111/jdv.15291. Epub 2018 Nov 13. J Eur Acad Dermatol Venereol. 2019. PMID: 30317662 No abstract available.

8

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L. Kimball AB, et al. Among authors: krueger gg. Br J Dermatol. 2018 Oct;179(4):984-986. doi: 10.1111/bjd.16737. Epub 2018 Jul 20. Br J Dermatol. 2018. PMID: 29747219 No abstract available.

9

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Langley RG, et al. Among authors: krueger gg. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16. J Eur Acad Dermatol Venereol. 2013. PMID: 23157612

10

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.

Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees AS, Gelfand JM. Duffin KC, et al. Among authors: krueger gg. Br J Dermatol. 2014 Mar;170(3):672-680. doi: 10.1111/bjd.12745. Br J Dermatol. 2014. PMID: 24266717 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results